logo-loader

UPDATE - TyraTech hails US launch of Novartis-backed livestock product

Published: 07:01 30 Apr 2014 EDT

usamap350_5360990eb83d1

---ADDS SHARE PRICE---

The milestones are coming thick and fast for TyraTech (LON:TYR), the specialist in nature-derived insect and parasite control products.

This morning the group announced the US launch of Natunex, a new line of non-toxic biocides that provides highly effective and fast insect control in livestock.

The product will be distributed by Novartis Animal Health in the States, and taps both companies into a market predicted to be worth US$1bn by 2016.

Chief executive Bruno Jactel said: "TyraTech is excited about delivering the Natunex product line, which addresses the increased demand from livestock producers for efficacious, safe and more practical solutions to control insects and parasites.

“The partnership with Novartis Animal Health will make Natunex immediately available across Novartis' network of US livestock producers, with a global roll-out forthcoming.

“In addition, this relationship demonstrates the effectiveness and quality of TyraTech's technology and products. Natunex represents a significant step forward in non-toxic, environmentally friendly and highly effective pest control."

The announcement reveals it is business as usual for the Swiss drugs giant, which is in the formative stages of a sale of its animal health unit to Eli Lilly.

It is just one of a series of announcements that show TyraTech is turning its early promise into commercial reality.

At the end of last month its Vamousse treatment for head lice went on sale in 4,000 Wal-Mart stores.

Vamousse and Natunex are just two of a number of natural oil-based products lined up for the US market. These include a preventative shampoo for head lice to follow Vamousse that it hopes will transform the market by switching the emphasis to prevention rather than treatment.

Another new product is a natural oil-based repellent for mosquitoes and ticks. The personal repellent market is worth about US$200mln and dominated by products based on DEET, a pesticide developed by the Americans for the Vietnam War.

The shares, up 130% in the year to date, added a further 1% to stand at 11.6p each at noon.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 19 minutes ago